Dr. Kiyoshi Tachikawa is an accomplished scientist, C-suite executive leader and board member with over 25 years of experience in RNA therapeutics and a broad range of therapeutic modalities, including mRNA, siRNA, oligonucleotides, protein engineering, and gene regulation technologies. He has led and contributed to the development of more than 60 platform technologies and product assets across indications such as infectious disease, metabolic disorders, fibrosis, and cancer.

At SlingstoneBio, he serves on the Board of Directors and provides scientific guidance across multiple modalities and development strategies.

He previously served in senior R&D roles at Arcturus Therapeutics and as board member on Japan-based ARCALIS joint-venture, where he played a central role in advancing multiple RNA-based programs, including the development of the first self-amplifying mRNA COVID-19 vaccine approved in Japan and the EU. Dr. Tachikawa also held scientific leadership positions at Pfizer Japan, Nitto Denko, and UC San Diego, with additional academic training at MIT and Tufts Medical School.He holds over 35 issued patents and has published extensively in the fields of RNA therapeutics and synthetic biology. Dr. Tachikawa earned his MS and PhD in Natural Product Chemistry from Tokyo University of Agriculture and Technology and a BSc in Pharmaceutical Science from Meiji Pharmaceutical University.